Matinas BioPharma Holdings, Inc.
MTNBMatinas BioPharma Holdings, Inc. is a biopharmaceutical company focused on developing lipid-based therapies for underserved medical needs, particularly in infectious diseases, cardiovascular, and neurological disorders. The company utilizes its proprietary lipid nanotechnology platform to develop novel oral drug delivery systems aimed at improving the safety and efficacy of existing medications.
Company News
Matinas BioPharma received a notice from NYSE American on June 24, 2026, regarding non-compliance with continued listing standards due to insufficient stockholders' equity relative to accumulated losses. The company submitted a compliance plan and has been granted until October 2, 2027, to regain compliance. Failure to meet standards by the deadl...
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial n...
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonu...
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025
